A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

TerminatedOBSERVATIONAL
Enrollment

6

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

April 28, 2025

Study Completion Date

April 28, 2025

Conditions
Venous Thromboembolism
Trial Locations (10)

29425

MUSC (Medical university of South Carolina), Charleston

33701

Johns Hopkins All Children's Hospital, St. Petersburg

37232

Vanderbilt University, Nashville

45229

Cincinnati Children's Hospital, Cincinnati

45404

Dayton Children's Hospital, Dayton

46260

Indiana Hemophilia & Thrombrosis Center, Indianapolis

78723

Dell Children's Ascension, Austin

92093

University of California, San Diego, La Jolla

92123

Rady Children's Hospital, San Diego

06519

Yale University School of Medicine, New Haven

Sponsors
All Listed Sponsors
collaborator

Children's Hospital Acquired Thrombosis consortium

UNKNOWN

lead

Boehringer Ingelheim

INDUSTRY

NCT05966740 - A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot | Biotech Hunter | Biotech Hunter